Parabilis pursued a potentially record-setting Nasdaq debut, launching an IPO valued at about $670 million and earmarking proceeds to fund a cancer drug program. The company’s move comes amid ongoing investor attention on large IPOs even as AI-driven offerings dominate headlines elsewhere. The listing is framed as a financing milestone for a drug developer seeking to translate funding into pipeline execution—particularly at a time when the public biotech market remains selective. Parabilis’ capital raise adds to a still-active IPO window for companies with clear clinical narratives. For biotech investors, the IPO underscores how runway-driven strategies and near-term development catalysts are currently winning market attention, even in a consolidated public landscape.